A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity

Am J Med. 2004 Sep 15;117(6):398-405. doi: 10.1016/j.amjmed.2004.04.009.

Abstract

Purpose: To compare the effects of a low-carbohydrate diet and a conventional (fat- and calorie-restricted) diet on lipoprotein subfractions and inflammation in severely obese subjects.

Methods: We compared changes in lipoprotein subfractions and C-reactive protein levels in 78 severely obese subjects, including 86% with either diabetes or metabolic syndrome, who were randomly assigned to either a low-carbohydrate or conventional diet for 6 months.

Results: Subjects on a low-carbohydrate diet experienced a greater decrease in large very low-density lipoprotein (VLDL) levels (difference = -0.26 mg/dL, P = 0.03) but more frequently developed detectable chylomicrons (44% vs. 22%, P = 0.04). Both diet groups experienced similar decreases in the number of low-density lipoprotein (LDL) particles (difference = -30 nmol/L, P = 0.74) and increases in large high-density lipoprotein (HDL) concentrations (difference = 0.70 mg/dL, P = 0.63). Overall, C-reactive protein levels decreased modestly in both diet groups. However, patients with a high-risk baseline level (>3 mg/dL, n = 48) experienced a greater decrease in C-reactive protein levels on a low-carbohydrate diet (adjusted difference = -2.0 mg/dL, P = 0.005), independent of weight loss.

Conclusion: In this 6-month study involving severely obese subjects, we found an overall favorable effect of a low-carbohydrate diet on lipoprotein subfractions, and on inflammation in high-risk subjects. Both diets had similar effects on LDL and HDL subfractions.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biomarkers / blood
  • Body Composition
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / metabolism*
  • Caloric Restriction*
  • Chylomicrons / drug effects
  • Chylomicrons / metabolism
  • Diabetes Mellitus / diet therapy
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / metabolism
  • Diet, Fat-Restricted*
  • Dietary Carbohydrates / administration & dosage*
  • Dietary Carbohydrates / metabolism*
  • Female
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Lipoproteins / drug effects
  • Lipoproteins / metabolism*
  • Lipoproteins, HDL / drug effects
  • Lipoproteins, HDL / metabolism
  • Lipoproteins, LDL / drug effects
  • Lipoproteins, LDL / metabolism
  • Lipoproteins, VLDL / drug effects
  • Lipoproteins, VLDL / metabolism
  • Male
  • Middle Aged
  • Obesity / diet therapy*
  • Obesity / epidemiology
  • Obesity / metabolism*
  • Pennsylvania
  • Risk Factors
  • Severity of Illness Index
  • Treatment Outcome
  • Weight Loss

Substances

  • Biomarkers
  • Chylomicrons
  • Dietary Carbohydrates
  • Hypolipidemic Agents
  • Lipoproteins
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • C-Reactive Protein